99 related articles for article (PubMed ID: 14718382)
1. Polo-like kinase (Plk) 1: a novel target for the treatment of prostate cancer.
Ahmad N
FASEB J; 2004 Jan; 18(1):5-7. PubMed ID: 14718382
[TBL] [Abstract][Full Text] [Related]
2. Silencing of polo-like kinase (Plk) 1 via siRNA causes induction of apoptosis and impairment of mitosis machinery in human prostate cancer cells: implications for the treatment of prostate cancer.
Reagan-Shaw S; Ahmad N
FASEB J; 2005 Apr; 19(6):611-3. PubMed ID: 15661849
[TBL] [Abstract][Full Text] [Related]
3. Polo-like kinase (Plk) 1 as a target for prostate cancer management.
Reagan-Shaw S; Ahmad N
IUBMB Life; 2005 Oct; 57(10):677-82. PubMed ID: 16223707
[TBL] [Abstract][Full Text] [Related]
4. Silencing of polo-like kinase (Plk) 1 via siRNA causes inhibition of growth and induction of apoptosis in human esophageal cancer cells.
Bu Y; Yang Z; Li Q; Song F
Oncology; 2008; 74(3-4):198-206. PubMed ID: 18714168
[TBL] [Abstract][Full Text] [Related]
5. Downregulation of human polo-like kinase activity by antisense oligonucleotides induces growth inhibition in cancer cells.
Spänkuch-Schmitt B; Wolf G; Solbach C; Loibl S; Knecht R; Stegmüller M; von Minckwitz G; Kaufmann M; Strebhardt K
Oncogene; 2002 May; 21(20):3162-71. PubMed ID: 12082631
[TBL] [Abstract][Full Text] [Related]
6. Polo-like kinase inhibitors: an emerging opportunity for cancer therapeutics.
Chopra P; Sethi G; Dastidar SG; Ray A
Expert Opin Investig Drugs; 2010 Jan; 19(1):27-43. PubMed ID: 20001553
[TBL] [Abstract][Full Text] [Related]
7. Polo-like kinases (Plks) and cancer.
Takai N; Hamanaka R; Yoshimatsu J; Miyakawa I
Oncogene; 2005 Jan; 24(2):287-91. PubMed ID: 15640844
[TBL] [Abstract][Full Text] [Related]
8. Effect of antisense RNA targeting polo-like kinase 1 on cell cycle and proliferation in A549 cells.
Zhou Q; Bai M; Su Y
Chin Med J (Engl); 2004 Nov; 117(11):1642-9. PubMed ID: 15569479
[TBL] [Abstract][Full Text] [Related]
9. Getting in and out of mitosis with Polo-like kinase-1.
van Vugt MA; Medema RH
Oncogene; 2005 Apr; 24(17):2844-59. PubMed ID: 15838519
[TBL] [Abstract][Full Text] [Related]
10. Inhibition of polo-like kinase 1 by blocking polo-box domain-dependent protein-protein interactions.
Reindl W; Yuan J; Krämer A; Strebhardt K; Berg T
Chem Biol; 2008 May; 15(5):459-66. PubMed ID: 18482698
[TBL] [Abstract][Full Text] [Related]
11. Genetic approach to evaluate specificity of small molecule drug candidates inhibiting PLK1 using zebrafish.
Zhong H; Xin S; Zhao Y; Lu J; Li S; Gong J; Yang Z; Lin S
Mol Biosyst; 2010 Aug; 6(8):1463-8. PubMed ID: 20625580
[TBL] [Abstract][Full Text] [Related]
12. Polo-like kinase 1 is overexpressed in prostate cancer and linked to higher tumor grades.
Weichert W; Schmidt M; Gekeler V; Denkert C; Stephan C; Jung K; Loening S; Dietel M; Kristiansen G
Prostate; 2004 Aug; 60(3):240-5. PubMed ID: 15176053
[TBL] [Abstract][Full Text] [Related]
13. Distinct concentration-dependent effects of the polo-like kinase 1-specific inhibitor GSK461364A, including differential effect on apoptosis.
Gilmartin AG; Bleam MR; Richter MC; Erskine SG; Kruger RG; Madden L; Hassler DF; Smith GK; Gontarek RR; Courtney MP; Sutton D; Diamond MA; Jackson JR; Laquerre SG
Cancer Res; 2009 Sep; 69(17):6969-77. PubMed ID: 19690138
[TBL] [Abstract][Full Text] [Related]
14. Targeting Polo-like kinase in cancer therapy.
Degenhardt Y; Lampkin T
Clin Cancer Res; 2010 Jan; 16(2):384-9. PubMed ID: 20068088
[TBL] [Abstract][Full Text] [Related]
15. Differential regulation of polo-like kinase 1, 2, 3, and 4 gene expression in mammalian cells and tissues.
Winkles JA; Alberts GF
Oncogene; 2005 Jan; 24(2):260-6. PubMed ID: 15640841
[TBL] [Abstract][Full Text] [Related]
16. [Effect of antisense RNA targeting Polo-like kinase 1 on cell cycle of lung cancer cell line A549].
Zhou Q; Bai M; Su Y
Ai Zheng; 2005 Feb; 24(2):149-54. PubMed ID: 15694023
[TBL] [Abstract][Full Text] [Related]
17. Oncogenic effect of Polo-like kinase 1 expression in human gastric carcinomas.
Jang YJ; Kim YS; Kim WH
Int J Oncol; 2006 Sep; 29(3):589-94. PubMed ID: 16865274
[TBL] [Abstract][Full Text] [Related]
18. Polo-like kinase isoform expression is a prognostic factor in ovarian carcinoma.
Weichert W; Denkert C; Schmidt M; Gekeler V; Wolf G; Köbel M; Dietel M; Hauptmann S
Br J Cancer; 2004 Feb; 90(4):815-21. PubMed ID: 14970859
[TBL] [Abstract][Full Text] [Related]
19. Polo-like kinases and DNA damage checkpoint: beyond the traditional mitotic functions.
Bahassi el M
Exp Biol Med (Maywood); 2011 Jun; 236(6):648-57. PubMed ID: 21558091
[TBL] [Abstract][Full Text] [Related]
20. Beta-hydroxyisovalerylshikonin induces apoptosis in human leukemia cells by inhibiting the activity of a polo-like kinase 1 (PLK1).
Masuda Y; Nishida A; Hori K; Hirabayashi T; Kajimoto S; Nakajo S; Kondo T; Asaka M; Nakaya K
Oncogene; 2003 Feb; 22(7):1012-23. PubMed ID: 12592388
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
